NuvOx Pharma Generates Positive Preclinical Data Showing NanO2TM Boosts Efficacy of Immunotherapy
The latest from NuvOx
NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM
NuvOx Pharma Announces Issuance of New Patent Covering a New Method of Treating Cancer
Tucson's NuvOx adds plant to make drugs in-house
NuvOx Completes Construction of Expanded Manufacturing Facility
NuvOx Pharma Announces Appointment of Jon S. Saxe to Its Board of Directors
Hunniwell Lake Ventures Spotlights NuvOx
Health Canada Allows Phase IIa Clinical Trial in COVID-19 Patients with Respiratory Failure
NuvOx Expands Production Line
NuvOx Pharma’s NanO2 Shows Positive Results in Phase Ib/II Stroke Trial
NuvOx Wins TechConnect Defense Innovation Award
NuvOx Pharma wins AZBio Fast Lane Award
National Cancer Institute Grants $3M to NuvOx Pharma for Phase II Clinical Trial in Brain Cancer
NuvOx Wins MedCity INVEST Perfect Pitch Contest
NuvOx wins Venture Madness competition and $60,000 prize.